Effects of bee venom on cholecystokinin octapeptide-induced acute pancreatitis in rats.
OBJECTIVE
Bee venom (BV) has frequently been used as a remedy for inflammatory diseases. The aim of this study was to investigate the effect of BV on cholecystokinin octapeptide (CCK-8)-induced acute pancreatitis (AP) in rats.


METHODS
The BV pretreatment group: 0.25 mg/kg BV was administered subcutaneously, followed by 75 mug/kg CCK-8 subcutaneously 3 times after 1, 3, and 5 hours. This whole procedure was repeated for 5 days.


METHODS
CCK-8 subcutaneously 3 times after 1, 3, and 5 hours for 5 days. The BV posttreatment group: CCK-8 subcutaneously 3 times at an interval of 2 hours for 3 days, and then 0.25 mg/kg of BV was administered subcutaneously.


METHODS
CCK-8 subcutaneously 3 times at an interval of 2 hours for 3 days.


RESULTS
The BV pretreatment and posttreatment ameliorated many of the examined laboratory parameters (the pancreatic weight [PW]/body weight [BW] ratio, the serum amylase and lipase activity) and reduced histological damages in pancreas. Furthermore, BV pretreatment reduced the production of tumor necrosis factor-alpha, interleukin 1, and interleukin 6 and also decreased pancreatic nuclearfactor-kappaB binding activity compared with saline-treated group in the AP model. The BV also increased heat shock protein 60 (HSP60) and heat shock protein 72 (HSP72) compared with the saline-treated group in the AP model.


CONCLUSIONS
These findings suggest that the anti-inflammatory effect of BV in CCK-8-induced AP seems to be mediated by inhibiting nuclear factor-kappaB binding activity, and that BV may have a protective effect against AP.
Seo
Sang-Wan
SW
Department of Herbology, College of Oriental Medicine, Wonkwang University, Iksan, Jeonbuk 570-749, South Korea.
Jung
Won-Seok
WS
Lee
Sung-Eon
SE
Choi
Chang-Min
CM
Shin
Byung-Chul
BC
Kim
Eun-Kyung
EK
Kwon
Kang-Beom
KB
Hong
Seung-Heon
SH
Yun
Ki-Jung
KJ
Park
Rae-Kil
RK
Shin
Min-Kyo
MK
Song
Ho-Joon
HJ
Park
Sung-Joo
SJ
D000208:Acute Disease; D000681:Amylases / Q000097:blood; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001514:Bee Venoms / Q000008:administration & dosage / Q000494:pharmacology*; D001835:Body Weight; D018834:Chaperonin 60 / Q000378:metabolism; D004195:Disease Models, Animal; D050884:HSP72 Heat-Shock Proteins / Q000378:metabolism; D007279:Injections, Subcutaneous; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008049:Lipase / Q000097:blood; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D009929:Organ Size; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010195:Pancreatitis / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D012720:Severity of Illness Index; D012844:Sincalide; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D000893:Anti-Inflammatory Agents; D001514:Bee Venoms; D018834:Chaperonin 60; D050884:HSP72 Heat-Shock Proteins; D007375:Interleukin-1; D015850:Interleukin-6; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D008049:Lipase; D000681:Amylases; D012844:Sincalide